Follow
Rabeea F. Omar
Rabeea F. Omar
CHU de Quebec-Universite Laval
Verified email at crchul.ulaval.ca
Title
Cited by
Cited by
Year
Mechanism of ochratoxin A stimulated lipid peroxidation
RF Omar, BB Hasinoff, F Mejilla, AD Rahimtula
Biochemical Pharmacology 40 (6), 1183-1191, 1990
1711990
In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses
J Piret, J Lamontagne, J Bestman-Smith, S Roy, P Gourde, A Désormeaux, ...
Journal of clinical microbiology 38 (1), 110-119, 2000
1662000
Role of cytochrome P‐450 in ochratoxin a‐stimulated lipid peroxidation
RF Omar, AD Rahimtula, H Bartsch
Journal of Biochemical Toxicology 6 (3), 203-209, 1991
751991
Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A
RF Omar, HV Gelboin, AD Rahimtula
Biochemical pharmacology 51 (3), 207-216, 1996
681996
Thermoreversible Gel Formulations Containing Sodium Lauryl Sulfate or n-Lauroylsarcosine as Potential Topical Microbicides against Sexually Transmitted Diseases
S Roy, P Gourde, J Piret, A Désormeaux, J Lamontagne, C Haineault, ...
Antimicrobial agents and chemotherapy 45 (6), 1671-1681, 2001
522001
Comparative Study of Mechanisms of Herpes Simplex Virus Inactivation by Sodium Lauryl Sulfate and n-Lauroylsarcosine
J Piret, S Roy, M Gagnon, S Landry, A Désormeaux, RF Omar, ...
Antimicrobial Agents and Chemotherapy 46 (9), 2933-2942, 2002
492002
NADPH-cytochrome-P-450 reductase promoted hydroxyl radical production by the iron (III)-ochratoxin A complex
BB Hasinoff, AD Rahimtula, RF Omar
Biochimica et Biophysica Acta (BBA)-General Subjects 1036 (1), 78-81, 1990
481990
Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9
N Gagné, H Cormier, RF Omar, A Désormeaux, P Gourde, MJ Tremblay, ...
Sexually transmitted diseases 26 (3), 177-183, 1999
441999
Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device
C Haineault, P Gourde, S Perron, A Désormeaux, J Piret, RF Omar, ...
Biology of reproduction 69 (2), 687-694, 2003
382003
A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom® formulations in Cameroonian women
FX Mbopi-Keou, S Trottier, RF Omar, NN Nkele, S Fokoua, ER Mbu, ...
Contraception 81 (1), 79-85, 2010
352010
Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment
J Bestman-Smith, J Piret, A Désormeaux, MJ Tremblay, RF Omar, ...
Antimicrobial agents and chemotherapy 45 (8), 2229-2237, 2001
312001
Ribavirin potentiates the efficacy and toxicity of 2', 3'-dideoxyinosine in the murine acquired immunodeficiency syndrome model.
P Harvie, RF Omar, N Dusserre, N Lansac, A Desormeaux, P Gourde, ...
Journal of Pharmacology and Experimental Therapeutics 279 (2), 1009-1017, 1996
281996
Applicator for the delivery of topical formulations into mucosal cavities
MG Bergeron, A Desormeaux, RF Omar
US Patent 7,465,295, 2008
272008
Safety, tolerance and acceptability of the Invisible Condom® and its vaginal applicator in healthy women and their male sexual partners
S Trottier, RF Omar, A Désormeaux, J Drouin, MT Gagnon, F Vezina, ...
Contraception 76 (2), 117-125, 2007
252007
The future of microbicides
RF Omar, MG Bergeron
International Journal of Infectious Diseases 15 (10), e656-e660, 2011
242011
Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2
J Piret, N Gagne, S Perron, A Desormeaux, MJ Tremblay, P Gourde, ...
Sexually transmitted diseases 28 (8), 484-491, 2001
212001
Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations …
MG Bergeron, A Désormeaux, RF Omar, J Juhasz
US Patent 6,500,460, 2002
202002
Distribution of a vaginal gel (Invisible Condom®) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators …
RF Omar, S Trottier, G Brousseau, A Lamarre, A Gagnon, MG Bergeron
Contraception 77 (6), 447-455, 2008
182008
Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations …
MG Bergeron, A Désormeaux, RF Omar, J Juhasz
US Patent 7,192,607, 2007
182007
Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model
P Harvie, RF Omar, N Dusserre, A Désormeaux, P Gourde, M Tremblay, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 12 (5), 451-461, 1996
171996
The system can't perform the operation now. Try again later.
Articles 1–20